Review article: new pharmacological agents for the treatment of gastro-oesophageal reflux disease.
Proton pump inhibitors, which act at the terminal point of acid secretion--the H+, K+-ATPase--are currently the most effective pharmacological treatments available for reflux disease. Despite the efficacy of the proton pump inhibitors, there is still potential for clinical improvement in gastro-oesophageal reflux disease pharmacotherapy. Faster onset of complete acid inhibition and improved duration of efficacy are two potential areas for improvement A number of novel pharmaceutical agents are currently undergoing clinical evaluation for the treatment of gastro-oesophageal reflux disease. These include transient lower oesophageal sphincter relaxation-reducing agents, serotonergic agents/prokinetics, potassium-competitive acid blockers, mucosal protectants, histamine H3 agonists and anti-gastrin agents. One or more of these drug groups may represent the future medical therapy for gastro-oesophageal reflux disease, should they prove effective in the clinical setting. This review summarizes the state of the art with these agents.
Vakil
N
N
University of Wisconsin Medical School, Madison, WI, USA. nvakil@wisc.edu
D005753:Gastric Mucosa / Q000187:drug effects; D005755:Gastrins / Q000037:antagonists & inhibitors; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000627:therapeutic use; D017442:Histamine Agonists / Q000627:therapeutic use; D006801:Humans; D054328:Proton Pump Inhibitors; D018490:Serotonin Agents / Q000627:therapeutic use; D000254:Sodium-Potassium-Exchanging ATPase / Q000032:analysis / Q000037:antagonists & inhibitors
D005755:Gastrins; D005765:Gastrointestinal Agents; D017442:Histamine Agonists; D054328:Proton Pump Inhibitors; D018490:Serotonin Agents; D000254:Sodium-Potassium-Exchanging ATPase